Symbols / ATHE
ATHE Chart
About
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 62.17M |
| Enterprise Value | 30.59B | Income | -12.15M | Sales | 5.44M |
| Book/sh | 0.00 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -8.67 | PEG | — |
| P/S | 11.43 | P/B | 972.08 | P/C | — |
| EV/EBITDA | -2090.36 | EV/Sales | 5624.05 | Quick Ratio | 12.62 |
| Current Ratio | 12.98 | Debt/Eq | 0.37 | LT Debt/Eq | — |
| EPS (ttm) | -0.61 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | 80.90% | Earnings | 2015-08-25 20:00 | ROA | -28.09% |
| ROE | -43.23% | ROIC | — | Gross Margin | 97.66% |
| Oper. Margin | -185.73% | Profit Margin | -223.35% | Shs Outstand | 18.13M |
| Shs Float | 7.04B | Short Float | 0.01% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 7.00 | 52W Low | 2.52 |
| Beta | -0.02 | Avg Volume | 14.14K | Volume | 2.66K |
| Target Price | $11.00 | Recom | Strong_buy | Prev Close | $3.33 |
| Price | $3.43 | Change | 3.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$3.43
Latest analyst target
3. DCF / Fair value
$-8.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.43
Low
$10.00
High
$12.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | init | Canaccord Genuity | — → Speculative Buy | — |
| 2025-01-30 | main | Maxim Group | Buy → Buy | $12 |
| 2024-12-12 | init | Maxim Group | — → Buy | $8 |
| 2024-03-07 | reit | Benchmark | Speculative Buy → Speculative Buy | $4 |
| 2023-06-05 | main | Ladenburg Thalmann | Buy → Buy | $10 |
- Experimental MSA drug ATH434 inches toward Phase 3 on stronger data - Stock Titan Fri, 30 Jan 2026 08
- Europen shares little changed as software rout counters relief rally in miners - Reuters ue, 03 Feb 2026 08
- Is ADP (ADP) Undervalued After Its Recent Pullback? A Fresh Look at the Stock’s Valuation - Yahoo Finance ue, 23 Dec 2025 08
- There’s a new saloon at the Stock Show, and BBQ from a top chef - The Denver Post Fri, 09 Jan 2026 08
- Meet the team who treats injured cowboys at the stock show - 9News hu, 22 Jan 2026 08
- Sports Bets at the Stock Exchange - Bloomberg.com ue, 07 Oct 2025 07
- Where to Eat During the National Western Stock Show - 5280 hu, 08 Jan 2026 08
- Aiming for first MSA therapy, Alterity targets $2.4B opportunity - Stock Titan Wed, 21 Jan 2026 08
- Morning Bid: Great stock rotation rolls on - Reuters Wed, 14 Jan 2026 08
- Eaton (ETN) Shares Pull Back—A Fresh Look at the Stock’s Current Valuation - Yahoo Finance Sat, 23 Aug 2025 07
- Alterity (NASDAQ: ATHE) schedules Nov. 19 presentation at Bell Potter virtual conference - Stock Titan Wed, 12 Nov 2025 08
- Morning Bid: Stocks slide from record highs as caution reigns - Reuters Mon, 03 Nov 2025 08
- European shares flat ahead of Fed decision; investors assess mixed corporate updates - Reuters Wed, 10 Dec 2025 08
- Breakthrough MSA Drug Trial Reaches Major Milestone: What's Next for This Rare Disease Treatment? - Stock Titan hu, 27 Mar 2025 07
- European shares subdued at close amid caution ahead of week's Fed rate decision - Reuters Mon, 08 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -20.13K | 78.35K | 280.44K | 816.73K |
| TaxRateForCalcs | 0.30 | 0.30 | 0.30 | 0.30 |
| NormalizedEBITDA | -12.13M | -19.52M | -15.20M | -17.81M |
| TotalUnusualItems | -67.11K | 261.15K | 934.80K | 2.72M |
| TotalUnusualItemsExcludingGoodwill | -67.11K | 261.15K | 934.80K | 2.72M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.15M | -19.12M | -13.81M | -12.85M |
| ReconciledDepreciation | 139.72K | 147.53K | 102.26K | 54.21K |
| EBITDA | -12.19M | -19.25M | -14.27M | -15.08M |
| EBIT | -12.33M | -19.40M | -14.37M | -15.14M |
| NetInterestIncome | 446.29K | 268.42K | 16.44K | 2.50K |
| InterestIncome | 446.29K | 268.42K | 16.44K | 2.50K |
| NormalizedIncome | -12.10M | -19.31M | -14.46M | -14.75M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.15M | -19.12M | -13.81M | -12.85M |
| TotalExpenses | 12.33M | 19.40M | 14.37M | 15.14M |
| RentExpenseSupplemental | 68.63K | 79.33K | 87.61K | |
| DilutedAverageShares | 10.66M | 6.08M | 24.28M | 4.01M |
| BasicAverageShares | 10.66M | 6.08M | 24.28M | 4.01M |
| DilutedEPS | -1.14 | -3.12 | -0.57 | -3.18 |
| BasicEPS | -1.14 | -3.12 | -0.57 | -3.18 |
| DilutedNIAvailtoComStockholders | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeCommonStockholders | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncome | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeIncludingNoncontrollingInterests | -12.15M | -19.12M | -13.81M | -12.85M |
| NetIncomeContinuousOperations | -12.15M | -19.12M | -13.81M | -12.85M |
| TaxProvision | 68.06K | 46.09K | 104.46K | 70.01K |
| PretaxIncome | -12.08M | -19.08M | -13.70M | -12.78M |
| OtherIncomeExpense | -192.38K | 56.52K | 649.73K | 2.36M |
| OtherNonOperatingIncomeExpenses | -125.27K | -204.63K | -285.07K | -364.67K |
| GainOnSaleOfSecurity | -67.11K | 261.15K | 934.80K | 2.72M |
| NetNonOperatingInterestIncomeExpense | 446.29K | 268.42K | 16.44K | 2.50K |
| InterestIncomeNonOperating | 446.29K | 268.42K | 16.44K | 2.50K |
| OperatingIncome | -12.33M | -19.40M | -14.37M | -15.14M |
| OperatingExpense | 12.33M | 19.40M | 14.37M | 15.14M |
| OtherOperatingExpenses | -2.12M | 5.24K | 27.30K | -452.96K |
| OtherTaxes | -5.44M | -4.02M | -3.91M | -4.67M |
| DepreciationAmortizationDepletionIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationAndAmortizationInIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationIncomeStatement | 139.72K | 147.53K | 102.26K | 54.21K |
| ResearchAndDevelopment | 14.40M | 18.64M | 13.20M | 14.75M |
| SellingGeneralAndAdministration | 5.34M | 4.62M | 4.95M | 5.46M |
| GeneralAndAdministrativeExpense | 5.34M | 4.62M | 4.95M | 5.46M |
| OtherGandA | 2.77M | 2.55M | 2.27M | 2.51M |
| InsuranceAndClaims | 549.41K | 676.22K | 721.73K | 655.99K |
| RentAndLandingFees | 68.63K | 79.33K | 87.61K | |
| SalariesAndWages | 2.03M | 1.40M | 1.89M | 2.21M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 9.13B | 5.25B | 2.44B | 2.41B |
| ShareIssued | 9.13B | 5.25B | 2.44B | 2.41B |
| TotalDebt | 155.46K | 159.04K | 210.38K | 117.49K |
| TangibleBookValue | 42.40M | 13.80M | 22.81M | 35.47M |
| InvestedCapital | 42.40M | 13.80M | 22.81M | 35.47M |
| WorkingCapital | 42.34M | 13.66M | 22.67M | 35.32M |
| NetTangibleAssets | 42.40M | 13.80M | 22.81M | 35.47M |
| CapitalLeaseObligations | 155.46K | 159.04K | 210.38K | 117.49K |
| CommonStockEquity | 42.40M | 13.80M | 22.81M | 35.47M |
| TotalCapitalization | 42.40M | 13.80M | 22.81M | 35.47M |
| TotalEquityGrossMinorityInterest | 42.40M | 13.80M | 22.81M | 35.47M |
| StockholdersEquity | 42.40M | 13.80M | 22.81M | 35.47M |
| OtherEquityInterest | 5.34M | 4.81M | 3.97M | 3.57M |
| GainsLossesNotAffectingRetainedEarnings | 3.57M | 2.75M | ||
| RetainedEarnings | -225.89M | -214.16M | -195.13M | -181.88M |
| CapitalStock | 262.95M | 223.15M | 213.97M | 213.79M |
| CommonStock | 262.95M | 223.15M | 213.97M | 213.79M |
| TotalLiabilitiesNetMinorityInterest | 3.62M | 5.43M | 4.50M | 5.89M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 88.55K | 51.91K | 122.71K | 73.61K |
| EmployeeBenefits | 0.00 | 19.50K | 13.75K | 9.77K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 0.00 | 19.50K | ||
| LongTermDebtAndCapitalLeaseObligation | 88.55K | 51.91K | 103.21K | 59.86K |
| LongTermCapitalLeaseObligation | 88.55K | 51.91K | 103.21K | 59.86K |
| CurrentLiabilities | 3.53M | 5.37M | 4.38M | 5.82M |
| OtherCurrentLiabilities | 139.00 | 100.00K | -26.92K | |
| CurrentDebtAndCapitalLeaseObligation | 66.91K | 107.13K | 107.18K | 57.63K |
| CurrentCapitalLeaseObligation | 66.91K | 107.13K | 107.18K | 57.63K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 875.91K | 530.70K | 729.20K | 656.27K |
| PayablesAndAccruedExpenses | 2.59M | 4.64M | 3.55M | 5.11M |
| CurrentAccruedExpenses | 2.02M | 4.02M | 1.77M | 2.36M |
| Payables | 573.81K | 611.56K | 1.78M | 5.11M |
| OtherPayable | 19.25K | 14.43K | 33.91K | 57.62K |
| TotalTaxPayable | 16.28K | 15.99K | 27.93K | 26.92K |
| AccountsPayable | 538.28K | 581.14K | 1.72M | 5.08M |
| TotalAssets | 46.03M | 19.22M | 27.32M | 41.36M |
| TotalNonCurrentAssets | 155.17K | 186.88K | 268.86K | 218.52K |
| NetPPE | 155.17K | 186.88K | 268.86K | 218.52K |
| AccumulatedDepreciation | -432.20K | -459.93K | -514.54K | -646.55K |
| GrossPPE | 155.17K | 186.88K | 728.79K | 733.06K |
| OtherProperties | 155.17K | 186.88K | 728.79K | 733.06K |
| CurrentAssets | 45.87M | 19.04M | 27.05M | 41.14M |
| OtherCurrentAssets | 41.81K | 40.67K | 39.76K | 10.23K |
| PrepaidAssets | 1.23M | 2.32M | 2.57M | 1.60M |
| Receivables | 3.94M | 4.04M | 8.67M | 4.73M |
| TaxesReceivable | 3.94M | 4.04M | 8.60M | 4.73M |
| AccruedInterestReceivable | 0.00 | 157.00 | 656.00 | 18.00 |
| AccountsReceivable | 0.00 | 65.23K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 40.66M | 12.64M | 15.77M | 34.81M |
| OtherShortTermInvestments | 7.50M | 0.00 | ||
| CashAndCashEquivalents | 33.16M | 12.64M | 15.77M | 34.81M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -11.45M | -12.61M | -20.04M | -12.43M |
| RepaymentOfDebt | -127.10K | -10.37K | -59.92K | -34.51K |
| IssuanceOfCapitalStock | 42.57M | 10.14M | 316.68K | 17.18M |
| CapitalExpenditure | -5.72K | -7.31K | -89.15K | -10.47K |
| EndCashPosition | 33.16M | 12.64M | 15.77M | 34.81M |
| BeginningCashPosition | 12.64M | 15.77M | 34.81M | 28.12M |
| EffectOfExchangeRateChanges | -198.38K | 260.36K | 914.94K | 2.81M |
| ChangesInCash | 20.72M | -3.40M | -19.95M | 3.88M |
| FinancingCashFlow | 39.67M | 9.22M | 124.34K | 16.30M |
| CashFlowFromContinuingFinancingActivities | 39.67M | 9.22M | 124.34K | 16.30M |
| NetOtherFinancingCharges | -2.77M | -918.02K | -132.41K | -836.97K |
| NetCommonStockIssuance | 42.57M | 10.14M | 316.68K | 17.18M |
| CommonStockIssuance | 42.57M | 10.14M | 316.68K | 17.18M |
| NetIssuancePaymentsOfDebt | -127.10K | -10.37K | -59.92K | -34.51K |
| NetLongTermDebtIssuance | -127.10K | -10.37K | -59.92K | -34.51K |
| LongTermDebtPayments | -127.10K | -10.37K | -59.92K | -34.51K |
| InvestingCashFlow | -7.50M | -5.72K | -36.46K | -89.15K |
| CashFlowFromContinuingInvestingActivities | -7.50M | -5.72K | -36.46K | -89.15K |
| NetOtherInvestingChanges | -29.15K | |||
| NetInvestmentPurchaseAndSale | -7.50M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -7.50M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | -5.72K | -7.31K | -89.15K |
| PurchaseOfPPE | 0.00 | -5.72K | -7.31K | -89.15K |
| OperatingCashFlow | -11.45M | -12.61M | -20.04M | -12.34M |
| CashFlowFromContinuingOperatingActivities | -11.45M | -12.61M | -20.04M | -12.34M |
| ChangeInWorkingCapital | -613.68K | 5.75M | -6.39M | 1.76M |
| ChangeInOtherWorkingCapital | 345.21K | -218.01K | 78.69K | 122.88K |
| ChangeInOtherCurrentLiabilities | -99.86K | -11.94K | 0.00 | 0.00 |
| ChangeInOtherCurrentAssets | 1.08M | 252.99K | -968.21K | -516.18K |
| ChangeInPayablesAndAccruedExpense | -2.04M | 1.10M | -1.56M | 2.60M |
| ChangeInPayable | -2.04M | 1.10M | -1.56M | 2.60M |
| ChangeInReceivables | 104.07K | 4.62M | -3.94M | -447.68K |
| OtherNonCashItems | 450.06K | 61.00 | 1.88M | |
| StockBasedCompensation | 979.92K | 881.95K | 966.57K | 1.51M |
| AssetImpairmentCharge | 0.00 | 0.00 | 10.23K | 0.00 |
| DepreciationAmortizationDepletion | 139.72K | 147.53K | 102.26K | 54.21K |
| DepreciationAndAmortization | 139.72K | 147.53K | 102.26K | 54.21K |
| Depreciation | 139.72K | 147.53K | 102.26K | 54.21K |
| OperatingGainsLosses | -259.43K | -261.15K | -917.65K | -2.81M |
| NetForeignCurrencyExchangeGainLoss | -259.43K | -261.15K | -917.65K | -2.81M |
| NetIncomeFromContinuingOperations | -12.15M | -19.12M | -13.81M | -12.85M |
| CashFlowsfromusedinOperatingActivitiesDirect | -11.45M | -12.61M | -20.04M | -12.34M |
| TaxesRefundPaidDirect | 5.56M | 8.53M | -103.45K | 4.08M |
| InterestReceivedDirect | 446.29K | 269.07K | 15.80K | 2.75K |
| InterestPaidDirect | 0.00 | -7.22K | -4.57K | -2.29K |
| ClassesofCashPayments | -17.53M | -21.45M | -20.05M | -16.92M |
| PaymentstoSuppliersforGoodsandServices | -17.46M | -21.39M | -19.94M | -16.88M |
| ClassesofCashReceiptsfromOperatingActivities | 5.63M | 8.58M | 4.58M | 371.36K |
| OtherCashReceiptsfromOperatingActivities | 454.12K | 158.13K | ||
| ReceiptsfromGovernmentGrants | 0.00 | 454.12K | 213.24K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ATHE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|